Abstract
Proteomics is an indispensable tool for disease biomarker discovery. It is widely used for the analysis of biological fluids such as cerebrospinal fluid (CSF), blood, and saliva, which further aids in our understanding of disease incidence and progression. CSF is often the biospecimen of choice in case of intracranial tumors, as rapid changes in the tumor microenvironment can be easily assessed due to its close proximity to the brain. On the contrary studies comprising of serum or plasma samples do not truly reflect the underlying molecular alterations due to the presence of protective blood-brain barrier. We have described in here the detailed workflows for two advanced proteomics techniques, namely, 2D-DIGE (two-dimensional difference in-gel electrophoresis) and iTRAQ (isobaric tag for relative and absolute quantitation), for CSF analysis. Both of these techniques are very sensitive and widely used for quantitative proteomics analysis.
Aishwarya A. Rao and Kanika Mehta are the joint first authors.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rao JS (2003) Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3(7):489–501
Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA (2001) Malignant glioma: genetics and biology of a grave matter. Genes Dev 15(11):1311–1333
Gladson CL, Prayson RA, Liu WM (2010) The pathobiology of glioma tumors. Annu Rev Pathol 5:33–50
Schittenhelm J (2017) Recent advances in subtyping tumors of the central nervous system using molecular data. Expert Rev Mol Diagn 17(1):83–94
Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS (2018) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro Oncol 20(suppl_4):iv1–iv86
Gollapalli K, Ray S, Srivastava R, Renu D, Singh P, Dhali S, BajpaiDikshit J, Srikanth R, Moiyadi A, Srivastava S (2012) Investigation of serum proteome alterations in human glioblastoma multiforme. Proteomics 14:2378–2390
Somasundaram K, Nijaguna MB, Kumar DM (2009) Serum proteomics of glioma: methods and applications. Expert Rev Mol Diagn 7:695–707
Gahoi N, Malhotra D, Moiyadi A, Varma SG, Gandhi MN, Srivastava S (2018) Multi-pronged proteomic analysis to study the glioma pathobiology using cerebrospinal fluid samples. Proteomics Clin Appl 3:e1700056
Brown KJ, Seol H, Pillai DK, Sankoorikal BJ, Formolo CA, Mac J, Edwards NJ, Rose MC, Hathout Y (2013) The human secretome atlas initiative: implications in health and disease conditions. Biochim Biophys Acta 1834(11):2454–2461
Verheul C, Kleijn A, Lamfers MLM (2017) Cerebrospinal fluid biomarkers of malignancies located in the central nervous system. Handb Clin Neurol 146:139–169
Shen F, Zhang Y, Yao Y, Hua W, Zhang HS, Wu JS, Zhong P, Zhou LF (2014) Proteomic analysis of cerebrospinal fluid: toward the identification of biomarkers for gliomas. Neurosurg Rev 37(3):367–380
Tan Z, Liu R, Zheng L, Hao S, Fu C, Li Z, Deng X, Jang T, Merchant M, Whitin JC, Guo M, Cohen HJ, Recht L, Ling XB (2015) Cerebrospinal fluid protein dynamic driver network: at the crossroads of brain tumorigenesis. Methods 83:36–43
Guo J, Sun Z, Xiao S, Liu D, Jin G, Wang E, Zhou J, Zhou J (2009) Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients. Cell Res 12:1401–1403
Khoonsari PE, Häggmark A, Lönnberg M, Mikus M, Kilander L, Lannfelt L, Bergquist J, Ingelsson M, Nilsson P, Kultima K, Shevchenko G (2016) Analysis of the cerebrospinal fluid proteome in Alzheimer’s disease. PLoS One 11(3):e0150672
Sjödin S, Hansson O, Öhrfelt A, Brinkmalm G, Zetterberg H, Brinkmalm A, Blennow K (2017) Mass spectrometric analysis of cerebrospinal fluid ubiquitin in Alzheimer’s disease and Parkinsonian disorders. Proteomics Clin Appl 11(11–12)
Dayon L, Núñez Galindo A, Wojcik J, Cominetti O, Corthésy J, Oikonomidi A, Henry H, Kussmann M, Migliavacca E, Severin I, Bowman GL, Popp J (2018) Alzheimer disease pathology and the cerebrospinal fluid proteome. Alzheimers Res Ther 10(1):66
Yuan X, Russell T, Wood G, Desiderio DM (2002) Analysis of the human lumbar cerebrospinal fluid proteome. Electrophoresis 7-8:1185–1196
Shalaby T, Achini F, Grotzer MA (2016) Targeting cerebrospinal fluid for discovery of brain cancer biomarkers. J Cancer Metastasis Treat 2:176–187
Marouga R, David S, Hawkins E (2005) The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 382:669
Unlü M, Morgan ME, Minden JS (1997) Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18(11):2071–2077
Gharbi S, Gaffney P, Yang A, Zvelebil MJ, Cramer R, Waterfield MD, Timms JF (2002) Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol Cell Proteomics 1(2):91–98
Ohlendieck K (ed) (2018) Difference gel electrophoresis methods and protocols. Methods in molecular biology, vol 1664. Humana Press, New York, NY, p 3
Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, Lewis S, Currie I (2003) A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 3(1):36–44
Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin DJ (2004) Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 3(12):1154–1169
Rappsilber J, Mann M, Ishihama Y (2007) Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc 2(8):1896–1906
Acknowledgment
We would like to thank the High-Resolution Mass Spectrometry-Based Proteomics Research and Training Facility at IIT Bombay supported by the Department of Biotechnology (BT/PR13114/INF/22/206/2015) for processing the samples submitted for protein identification and quantification.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Rao, A.A., Mehta, K., Gahoi, N., Srivastava, S. (2019). Application of 2D-DIGE and iTRAQ Workflows to Analyze CSF in Gliomas. In: Santamaría, E., Fernández-Irigoyen, J. (eds) Cerebrospinal Fluid (CSF) Proteomics. Methods in Molecular Biology, vol 2044. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9706-0_6
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9706-0_6
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9705-3
Online ISBN: 978-1-4939-9706-0
eBook Packages: Springer Protocols